Tracey Ryniec is the Value Stock Strategist for Zacks.com. She is also the Editor of the Insider Trader and Value Investor services. You can follow her on twitter at @TraceyRyniec and she also hosts ...

AbbVie's Phase 2 ELATE trial shows onabotulinumtoxinA improves tremor scores and meets all endpoints, offering a new option for essential tremor.

St. Louis Financial Planners Asset Management, LLC initiated a new stake in AbbVie ( ABBV -0.69%), acquiring 14,630 shares for an estimated $3.39 million in Q3 2025.

Short interest is the number of shares that have been sold short but have not yet been covered or closed out. Short selling is when a trader sells shares of a company they do not own, with the hope ...

AbbVie Inc. (NYSE:ABBV) is one of the best medical stocks to buy now. In a report released on September 25, Courtney Breen from Bernstein maintained a Hold rating on AbbVie Inc. (NYSE:ABBV) without ...

The stock's fall snapped a four-day winning streak.

A Delaware judge on Thursday allowed a pension fund to advance claims in a dispute over trades by Bain Capital LP and Perceptive Advisors LLC ahead of Cerevel Therapeutics Holdings Inc.‘s $8.7 billion ...

AbbVie Inc. (NYSE:ABBV) is included among the 12 Best Dividend Aristocrat Stocks to Invest in Right Now. AbbVie Inc. (NYSE:ABBV) is a global biopharmaceutical company that manufactures and markets ...

AbbVie has filed for U.S. Food and Drug Administration approval of its investigational pivekimab sunirine antibody-drug conjugate for the treatment of the rare blood cancer blastic plasmacytoid ...

AbbVie (ABBV) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of ...